News

Intrabody Delivered with Adeno-Associated Virus Blocking Gene Dysregulation Offers Hope in Treating Huntingtonís Disease

February 20th, 2017
ďWe think intrabodies will reach both of those hallmarks, both in specificity, to eliminate or reduce off target affects, as well as being very safe and therefore enabling one to go after a rage of targets that have previously really eluded drug development.Ē - Dr. Lee A. Henderson, Ph.D. Read Full Press Release



Press Release: Vybion Huntington's Disease Drug Patent receives Track I Status

January 30, 2017
Vybion, Inc. is pleased to announce that its patent application covering methods of use and composition for INT41 Gene Therapy received Track I status from the USPTO. The INT41 patent application covers several neurodegenerative diseases in addition to Huntington's Disease including Spinal Cerebellar Ataxia, Spinal Muscular Atrophy, and Alzheimer's. "Vybion is pleased to receive Track I status on INT41 and anticipates rapid review and allowance" said Lee Henderson, Vybion CEO.

Read Full Press Release



Press Release: Vybion New Drug Webinar for Huntington's Patients

January 27, 2017
Vybion (NY) conducted a webinar, sponsored by the Huntington's Disease Society of America (HSDA), for patients and caregivers on a new Gene Therapy drug called INT41. The company CEO described this new drug class called Intrabodies and how INT41 works in Huntington's Disease along with clinical development plans. The company believes that Intrabodies can achieve both the specificity and safety of monoclonal antibodies from which Intrabodies are developed and have numerous applications in disease that have "hard" targets.

Read Full Press Release



Vybionís Huntington Drug Neutralizes Critical Disease Driver

September 3, 2013
Vybion will present data on how its drug, INT41, alters a critical event in the development of Huntingtonís disease at the 7th Neurodegenerative Conditions Research & Development Conference in Boston on September 9-10, 2013. INT41 is an Intrabody drug delivered by Gene Therapy that blocks gene dysregulation in Huntingtonís Disease by neutralizing a toxic fragment of the Huntingtin mutant protein in the nucleus of the cell preventing gene dysregulation.

ďWe are extremely excited by these data linking INT41 results to specific molecular events in Huntingtonís pathology. INT41 provides a surgical approach to inactivate the event for which a growing body of evidence indicates occurs prior to symptoms and may be the driver of disease progressionĒ said Lee Henderson, Ph.D., the CEO of Vybion and a coauthor on the presentation. Vybion is pursuing the completion of preclinical development and expects to begin human clinical trials in the next 18 months.

About Vybion, Inc. Vybion is a development stage Company with proprietary technologies that form the core of our business strategy. Vybion uses proprietary technologies for Intrabody development to treat neurodegenerative diseases such as Huntington's, SBMA and SCA, and for target validation in signal transduction pathways and in multiple therapeutic areas. Vybion is advancing its novel research therapy for Huntingtonís disease, INT41, through preclinical development with the aim of initiating clinical studies in the near future.

Contact:
Lee A. Henderson, Ph.D.
lhenderson@vybion.com
Office: 607-266-0860

PharmCode for Precision in Target Validation

March 28, 2012
Vybion announces the availability of PharmCode for partnering. PharmCode provides precise and rapid targeting of protein-protein, dimerization, phosphorylation or allele specific intracellular events in a pharmacologically meaningful manner avoiding pleiotropic effects. Most targets have multiple interactions but PharmCode Intrabodies target single events and can assess pathway effects, pathway crosstalk and toxicity analogous to small molecules targeting the same event or interaction, unlike iRNA which affects multiple pathways by deleting or reducing gene expression. When coupled to biochemical readouts, cell-based assays and gene expression arrays, PharmCode expedites drug discovery and provides a complete picture for target validation. Vybionís programs in Huntingtonís disease, protein folding pathways and insulin resistant diabetes illustrate PharmCode capabilities.

Contacts:
Lee Henderson, Ph.D., CEO
Vybion
607-266-0860 ext 4
lhenderson@vybion.com

US Patent office to issue Patent No. 8,029,985 on October 4, 2011

September 28, 2011
Vybion has been notified by the US Patent office of the issue of Patent No. 8,029,985 on October 4, 2011 entitled "Amplified Bioassay". This Point of Care (POC) platform enables the simultaneous detection of antibody-antigen recognition for multiple analytes. Each signal is amplified by the release of vesicles containing thousands of labeled oligonucleotides each of which is capable of additional signal amplification depending on the configuration of the assay. The platform has applications in LFI and microfluidic formats. Vybion's Amplified Multiplexing technology platform, AmPlex, is available for out-licensing or development partnerships.

Vybion awarded $244,000

November 1, 2010
Vybion was awarded $244,000 through the Qualifying Therapeutic Discovery Project (QTDP) for ProCode development of therapeutic products. ProCode was recognized as a leading edge technology that will have a positive impact on the healthcare industry. QTDP is a program funded under the Patient Protection and Affordability Care Act signed into law on March 30, 2010.

Alliance with Meridian Life Sciences

October 25, 2010
Vybion announces an Alliance with Meridian Life Sciences for ProCode applications to the Biomarker and Diagnostic Industry. The Companies have already developed strong interest from Meridianís client base.

Vybion and ALS Biopharma announce a Strategic Alliance

October 20, 2010
Vybion and ALS Biopharma announce a Strategic Alliance based on Vybion NPEG technology to develop a biologic therapy for ALS and related neuropathies. Read full story »

Vybion receives grant award from NIH

December 3, 2009
Vybion receives grant award from NIH for ďRapid Isolation of High Affinity Human Antibodies from Large Synthetic LibrariesĒ. The $200,000 grant is part of the ongoing collaboration with Dr. Matthew DeLisa at Cornell University. The grant further develops Vybionís ProCode antibody drug discovery platform to fulfill its commercial potential.

Lee Henderson, Ph.D. to give presentation at PepCon Conference

November 1, 2009
Lee Henderson, Ph.D. was invited to give a presentation at the PepCon Conference in Beijing, China in late March. Dr. Henderson will focus his presentation on the ProCode antibody discovery and engineering platform.

Vybion file patent for novel pegylation technology to improve and fine tune the pharmacokinetic
properties of biologics

July 2009
Vybion file patent for novel pegylation technology to improve and fine tune the pharmacokinetic properties of biologics. Vybionís pegylation technology is up to 70% efficiency and >99% specificity on a single amino acid. Increased circulating half lives of over 10 fold (less than one day to 10 days) have been demonstrated in animal models. Vybionís NPEG technology will be used in the development of antibody-like drugs with Vybionís ProCode technology and is available for partnering and out-licensing.

Vybion receives $1.3M subcontract to develop diagnostics for Lassa Virus

Jun 10, 2009
Vybion has received a $1.3M subcontract on at $7.1M NIH Cooperative Agreement to develop diagnostics for Lassa Virus, a deadly hemorrhagic virus endemic in West Africa. Researchers at Tulane University, in collaboration with Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, have received a five-year $7.07 million grant from the National Institutes of Health (NIH) for continued development of detection kits for Lassa viral hemorrhagic fever, a serious disease spread by contact with infected rodents. Viral hemorrhagic fevers are characterized by fever and bleeding disorders and can progress to high fever and shock. Lassa fever is estimated to infect 300,000 to 500,000 people per year across West Africa, resulting in approximately 5,000 deaths.

This is the second grant awarded to Tulane for Lassa virus products. Also collaborating with Corgenix and Tulane in this grant are Autoimmune Technologies, LLC ( New Orleans), Vybion, Inc. (Ithaca, NY), and various partners in West Africa. Read full story »

Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board

October 1, 2008
Ithaca, October 1 -- Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board. Matthew DeLisa, Ph.D. is on the faculty of Cornell University in the Department of Chemical and Molecular Engineering and the inventor of ProCode. DeLisaís research group combines protein engineering with genetic and molecular biology approaches to address fundamental issues related to protein transport, protein folding and solubility, and protein synthesis. William Ball, Ph.D. is a member of the Department of Pharmacology and Cell Biophysics while Andrew Norman, Ph.D. is in the Department of Psychiatry and is Director of the Division of Neuroscience at the University of Cincinnati. Drs. Norman and Ball are the developers of CoMab, a high affinity antibody to cocaine. Drs. Norman and Ball have a longstanding interest in addiction therapies and the physiology of drug interactions.


Corgenix Announces Expansion of Hemorrhagic Fever Virus Product Development Program

Jul 10, 2008
Denver, July 10 -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an expansion of the collaborative effort for developing test kits for viral hemorrhagic fever (VHF) detection... Joining the collaboration is Vybion, Inc., an Ithaca, N.Y., based biotechnology company. Vybion CEO Lee Henderson, Ph.D., stated, "We are pleased to be able to work with Corgenix, Tulane and the other partners. With our deep experience in protein expression from bacterial and mammalian cells and our extensive technology portfolio, we will be able to provide the commercial scale-up for the recombinant protein efforts." Read full Routers story »


Vybion Awarded Monoclonal Antibody Development Contract.

April 11, 2007
Ithaca, NY: Vybion, Inc. was awarded a contract by P2D in Cincinnati as part of collaboration on an SBIR Phase II grant. Vybion is developing a humanized version of the monoclonal antibody genes, developing the expression lines and the process for manufacturing the product. The antibody, specific for cocaine, binds cocaine in the blood stream, causing cocaine in brain tissues to cross the blood brain barrier back into the blood where it remains bound to the antibody prior to detoxification in liver. More (4KB) »


Vybion Licenses ProCodeô Platform

January 22, 2007
Ithaca, NY: Vybion has exclusively licensed a drug development platform from Cornell University. The Platform, called ProCode, can be configured for monoclonal antibody selection, affinity maturation and library generation, for improving solubility and bioactivity of biopharmaceuticals, as well as identification and characterization of protein-protein interactions and discovery of protein drugs. ProCode offers several important advantages that strongly differentiate it from other technologies including dramatic reductions in drug development time, cost, and ease of use. More (5KB) »


Vybion Presents at PepTalk Conference

January 8, 2007
Vybion CEO, Lee Henderson, Ph.D., made a poster presentation at the annual PepTalk Conference in San Diego on the ProCode Technology with work done by Matthew DeLisa, Ph.D. and his group in the Department of Chemical and Molecular Engineering at Cornell University. The poster centered on the applications of the ProCode twin arginine transport system for affinity improvement of monoclonal antibodies and solubility improvement of a variety of biologics. Several examples of the technology were presented. ProCode is a Platform technology for drug development that saves time, cost and is easy to use as well.